The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: A meta-analysis

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 21, 2014, Pages 3291-3296

  Wu, Y ^a   Shao, N ^a   Shen, Z X ^b   Li, Q ^c   Wang, Y ^a   Li, C ^a   Ma, G ^a   Dong, J ^a   Lu, X J ^a   Feng, N H ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Geriatric Hospital   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Castration resistant prostate cancer; Overall survival; Time to PSA progression; Zibotentan

Indexed keywords

ZIBOTENTAN; ANTINEOPLASTIC AGENT; PYRROLIDINE DERIVATIVE;

ANEMIA; ARTICLE; BACKACHE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HEART FAILURE; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DISEASE COURSE; DISEASE FREE SURVIVAL; MALE; META ANALYSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84942237205     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics 2012. CA Cancer J Clin 2012;62:10-29.
2. FERLAY J, PARKIN DM, STELIAROVA-FOUCHER E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
3. PETRYLAK D P, TANGEN CM, HUSSAIN MH, LARA PN, JONES JA, TAPLIN ME, BURCH PA, BERRY D, MOINPOUR C, KOHLI M, BENSON MC, SMALL EJ, RAGHAVAN D, CRAWFORD ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
4. TANNOCK I F, DE WIT R, BERRY WR, HORTI J, PLUZANSKA A, CHI KN, OUDARD S, THEODORE C, JAMES ND, TURESSON I, ROSENTHAL MA, EISENBERGER MA. Doc-etaxel plus prednisone or mitoxantrone plus pred-nisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
5. BAGNATO A, NATALI PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004;2:16.
6. BAGNATO A, LOIZIDOU M, PFLUG BR, CURWEN J, GROWCOTT J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011;163:220-233.
7. JAMES ND, CATY A, PAYNE H, BORRE M, ZONNENBERG BA, BEUZEBOC P, MCINTOSH S, MORRIS T, PHUNG D, DAWSON NA. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zi-botentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010;106:966-973.
8. TRUMP DL, PAYNE H, MILLER K, DE BONO JS, STEPHENSON J, 3RD, BURRIS HA, 3RD, NATHAN F, TABOADA M, MORRIS T, HUBNER A. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate 2011;71:1264-1275.
9. NELSON JB, FIZAZI K, MILLER K, HIGANO C, MOUL JW, AKAZA H, MORRIS T, MCINTOSH S, PEMBERTON K, GLEAVE M. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metasta-tic to bone. Cancer 2012;118:5709-5718.
10. FIZAZI KS, HIGANO CS, NELSON JB, GLEAVE M, MILLER K, MORRIS T, NATHAN FE, MCINTOSH S, PEMBERTON K, MOUL JW. Phase III, randomized, placebo-controlled study of docetaxel in combination with zi-botentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31:1740-1747.
11. MILLER K, MOUL JW, GLEAVE M, FIZAZI K, NELSON JB, MORRIS T, NATHAN FE, MCINTOSH S, PEMBERTON K, HIGANO CS. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013;16:187-192.
12. MOHER D, PHAM B, JONES A, COOK DJ, JADAD AR, MOHER M, TUGWELL P, KLASSEN T P. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-613.
13. PARMAR MK, TORRI V, STEWART L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
14. ZINTZARAS E, IOANNIDIS J P. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-137.
15. YUSUF S, PETO R, LEWIS J, COLLINS R, SLEIGHT P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Car-diovasc Dis 1985;27:335-371.
16. BEGG CB, MAZUMDAR M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
17. KONSTAM MA, DE NOFRIO D. Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. Circulation 2004;109:143-145.
18. MCMURRAY JJ, TEERLINK JR, COTTER G, BOURGE RC, CLELAND JG, JONDEAU G, KRUM H, METRA M, O'CONNOR CM, PARKER JD, TORRE-AMIONE G, VAN VELDHUISEN DJ, LEWSEY J, FREY A, RAINISIO M, KOBRIN I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
19. JAMES ND, CATY A, BORRE M, ZONNENBERG BA, BEUZEBOC P, MORRIS T, PHUNG D, DAWSON NA. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55:1112-1123.
20. BASCH EM, SOMERFIELD MR, BEER TM, CARDUCCI MA, HIGANO CS, HUSSAIN MH, SCHER HI. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhor-monal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007;25:5313-5318.
21. CARDUCCI MA, PADLEY RJ, BREUL J, VOGELZANG NJ, ZONNENBERG BA, DALIANI DD, SCHULMAN CC, NABULSI AA, HUMERICKHOUSE RA, WEINBERG MA, SCHMITT JL, NELSON JB. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-689.
22. CARDUCCI MA, SAAD F, ABRAHAMSSON PA, DEARNALEY D P, SCHULMAN CC, NORTH SA, SLEEP DJ, ISAACSON JD, NELSON JB. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-1966.